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Abstract: Scope: To identify a metabolomic profile related to postprandial satiety sensations in-
volved in appetite control would help for a better understanding of the regulation of food intake.
Methods and Results: A cross-sectional analysis of plasma metabolites was conducted over 151
overweight/obese adults from the “Satiety Innovation”-SATIN study, a randomized clinical trial of a
12-week weight-loss maintenance period. Postprandial satiety sensations (3 h-iAUC) were assessed
by visual analogue scale (VAS) at the beginning and at the end of the study. Fasting plasma metabo-
lites were profiled using a targeted multiplatform metabolomics approach before each appetite
test meal. Associations between 124 metabolites and iAUC-satiety were assessed using elastic net
linear regression analyses. The accuracy of the multimetabolite weighted models for iAUC-VAS was
evaluated using a 10-fold cross-validation (CV) approach and the Pearson’s correlation coefficients
were estimated. Five and three metabolites were selected in the first and the second assessments,
respectively. Circulating glycine and linoleic acid concentrations were consistently and positively
associated with higher iAUC-satiety in both visits. Sucrose and sphingomyelins (C32:2, C38:1) were
negatively associated with iAUC-satiety in the first visit. The Pearson correlations coefficients be-
tween the metabolomic profiles and iAUC-satiety in the first and the second appetite assessments
were 0.37 and 0.27, respectively. Conclusion: Higher glycine and linoleic acid were moderately but
consistently associated with higher postprandial satiety in two different appetite assessments in
overweight and obese subjects.
Keywords: metabolomics; obesity; satiety
1. Introduction
Overweight and obesity are complex conditions developed from the interaction of
several factors including physiologic, metabolic, cellular, and molecular processes but also
cultural, socioeconomic, or behavioural aspects [1]. Strategies to control the increasing
obesity pandemic are limited in number and efficacy. Bariatric surgery in extreme obesity
is one of the most successful interventions, but with an associated risk of complications
and mortality [2]. Pharmacology has also provided specific therapies targeting peripheral
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hormones and neural pathways to individuals with body mass index (BMI) over 30 kg/m2
for whom their condition compromised health. Several of these drugs were withdrawn
due to unacceptable side effects [3]. However, because weight gain leading to obesity
arises when energy intake exceeds energy expenditure over a prolonged period of time,
to naturally limit calorie intake by targeting appetite sensations could be a successful
strategy to promote weight management for the majority of people with overweight or
obesity [4].
Impaired appetite control is considered an important contributor to weight gain and
obesity development [5]. Evidence from clinical studies found a weaker satiety response to
a test meal in obese subjects, reporting no relationship between their eating behaviour and
appetite sensations [6]. These observations are not limited to obese subjects, and a “low
satiety phenotype” was described [7]. Therefore, a better understanding of the complex
biological processes involved in the control of appetite and food intake can contribute to a
better management of body weight and obesity.
Extensive research efforts during the last decades have revealed much information of
the neuroendocrine system and gut peptides related to satiety [3]. However, peripheral
physiology and metabolic events also play an important regulatory role. Metabolomics af-
ford profiling of hundreds of structurally and functionally diverse metabolites and provides
an instantaneous snapshot of the physiological status of the organism. Metabolites function
both as messengers by carrying data about the physiological environment, but also as trans-
ducers by directly controlling several physiological pathways. Although metabolomics
have been extensively used in nutrition research, their use for the understanding of com-
plex behaviours such as appetite is less explored. Thus, whereas the neuroendocrine
pathways related to hunger and satiety have been widely studied and markers of appetite
sensations described, metabolites related to the postprandial satiety period are unknown.
Indeed, a recent review has claimed metabolomic profiling as a potentially powerful but
relatively unexplored tool in the field of appetite [8]. Still, whether a specific metabolic
profile can distinguish participants with higher postprandial satiety remains unknown.
For this reason, we aimed to identify a metabolomic profile associated with postprandial
satiety sensations after a test meal.
2. Material and Methods
2.1. Study Design and Subjects
The present analysis was nested in the European Commission Project Satiety Inno-
vation (SATIN), a multicentre clinical trial aiming to evaluate the benefits of enhancing
satiety on medium-term weight regain prevention. Eligible participants were women
and men aged between 20 and 65 years with overweight/obesity (BMI 27–35 kg/m2)
without comorbidities. Participants with weight changes previous to the study (±3 kg in
the last three months), chronic medical conditions (type 1 or 2 diabetes, cardiovascular
diseases, hypertension, chronic kidney diseases, liver diseases, active inflammatory bowel
diseases, cancer, bariatric surgery, and other major surgical interventions, psychological or
behavioural problems, psychiatric disorders), drug addictions, alcohol consumption above
recommendations, and smoking (included smoking cessation within the last three months
previous to start the study) were excluded from the study.
Briefly, after an initial 8-week low-calorie diet (LCD) period, participants achieving
≥8% of weight loss were included in the subsequent 12-week randomized double-blind
parallel intervention phase for weight lost maintenance (WLM), with food products de-
signed to reduce appetite or matching control products as placebo. Detailed information
about study design, visits, and methods has been previously published [9].
The study and all procedures were conducted in accordance with the ethical principles
set forth in the current version of the Declaration of Helsinki (Fortaleza, Brazil, October
2013) and the International Conference on Harmonization E6 Good Clinical Practice (ICH-
GCP). The protocol was approved by the local institutional review boards and Ethics
Committees of all the recruiting centres (15-07-30/7assN2 for the Spanish centre and H-
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15008553 for the Danish centre). Participants received written and oral information about
the study procedures, and all participants provided written informed consent. All study
procedures were aligned between sites before initiation of the study and on-site monitoring
visits were carried out by an independent monitor. This trial was registered in clinicaltrials.
gov (identifier: NCT02485743).
From a total of 289 participants available at baseline, 151 participants achieving
>8% weight loss during the initial 8 weeks and with available blood samples and visual
analogue scale (VAS) data were considered in the current analysis (71 participants recruited
in Reus and 80 in Copenhagen). For the second appetite assessment conducted after a
12-weeks of weight maintenance period, data of 140 participants (66 from Reus and 74
from Copenhagen) were available (Figure 1).
Nutrients 2021, 13, x FOR PEER REVIEW 3 of 12 
 
The study and all procedures were conducted in accordance with the ethical princi-
ples set forth in the current version of the Declaration of Helsinki (Fortaleza, Brazil, Octo-
ber 2013) and the International Conference on Harmonization E6 Good Clinical Practice 
(ICH-GCP). The protocol was approved by the local institutional review boards and Ethics 
Committees of all the recruiting centres (15-07-30/7assN2 for the Spanish centre and H-
15008553 for the Danish centre). Participants received written and oral information about 
the study procedures, and all participants provided written informed consent. All study 
procedures were aligned between sites before initiation of the study and on-site monitor-
ing visits were carried out by an independent monitor. This trial was registered in clini-
caltrials.gov (identifier: NCT02485743). 
From a total of 289 participants available at baseline, 151 participants achieving >8% 
weight loss during the initial 8 weeks and with available blood samples and visual ana-
logue scale (VAS) data were considered in the current analysis (71 participants recruited 
in Reus and 80 in Copenhagen). For the second appetite assessment conducted after a 12-
weeks of weight maintenance period, data of 140 participants (66 from Reus and 74 from 
Copenhagen) were available (Figure 1). 
 
Figure 1. Flow-chart of the study. 
2.2. Assessment of Appetite 
An 8 h appetite was assessed during study visits scheduled at the beginning (first 
visit) and after a 12-weeks (second visit) post maintenance period by a self-reported ap-
petite evaluation, when subjects arrived to the centre facilities after an overnight fast and 
using the least strenuous means of transportation. For the appetite assessment, partici-
pants received a fixed breakfast meal (ham sandwich, coffee, milk, and orange juice), 
providing 478 Kcal corresponding to approximately 20% of the daily energy requirement 
for an average adult distributed as 55% of energy (E) as carbohydrates, 30%E as fat and 
15%E as protein [10]. Self-reported appetite ratings were assessed using either electronic 
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2.2. Assessment of Ap eti e
An 8 h appetite was se d during study visits scheduled at the beginnin (first vis t)
and after a 12-weeks (s cond visit) post main enance period by a self-reported appetite
evaluation, when subjects arrived to th centre faciliti s after an overnight fast and using
the least str nuous mean of transport tion. For the appetite assessment, partici nts
received a fixed breakfast meal (ham s ndwich, coffee, milk, and orange juice), providing
478 Kcal corresponding to approximately 20% of the daily energy requirement for an
average adult distributed as 55% of energy (E) as carbohydrates, 30%E as fat and 15%E
as protein [10]. Self-reported appetite ratings were assessed using either electronic VAS
(Lenovo® thinkpad® tablet 10; Evascale, build by Jakob Lund Laugesen, University of
Copenhagen) (used in Copenhagen) or pen-and-paper VAS (used in Reus), a standard
psychometric response scales of a 100-mm long horizontal line assessing feelings of satiety,
fullness, hunger, desire to eat, and prospective food consumption [11,12]. For the present
analysis, we considered appetite ratings pre- and immediately post-breakfast consumption
(after overnight fasting) and hourly for a postprandial period of 3 h, completed in a
controlled environment, with 0 indicating higher appetite/less satiety and 100 indicating
lower appetite/more satiety [13,14].
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2.3. Anthropometrical and Biochemical Measurements
All anthropometric measures were performed with the use of calibrated scales and by
trained staff. Body weight was measured with participants wearing light clothes, height
was measured on a wall-mounted stadiometer and BMI was then calculated. Waist circum-
ference was measured midway between the lowest rib and the iliac crest using a nonelastic
tape measure. Blood pressure was measured with participants in a resting position and
using calibrated automatic devices (Omron HEM705IT, Reus, Spain; A&D Medical UA-779,
Copenhagen, Denmark). Blood samples were collected in fasting conditions before starting
each appetite assessments. Plasma glucose and lipid profile were measured using standard
enzymatic automated methods (COBAS; Roche Diagnostics Ltd., Burgess Hill, UK).
2.4. Multiplatform Targeted Metabolomics
Metabolomic analysis was conducted in fasting blood samples using a multiplatform
approach including gas and liquid chromatography coupled to high-resolution mass
spectrometry (GC/LC-HRMS), and proton nuclear magnetic resonance (1H-NMR). The
Bravo Automated Liquid Handling Platform from Agilent Technologies was used to extract
metabolites from fasting plasma samples in 96-well format plates.
A protein precipitation extraction for GC-HRMS analysis was obtained by adding 400
of µL methanol: H2O (8:1) mixture to 100 µL of plasma. Supernatants were collected in
new 96 well plates that contain internal standards. This plate was dryness with a vacuum
centrifugation system (Speed Vac) and extracts were reconstituted with methoxyamine and
incubated 90 min at 37 ◦C. Metabolites were sylilated with N-Methyl-N-(trimethylsilyl)
trifluoroacetamide (MSTFA) + 1% trimethylchlorosilane (TMCS) at room temperature
during 60 min. For LC-HRMS analysis and NMR analyses, lipidic fraction was obtained
using a methanol/methyl-tert-butyl ether mixture. A small aliquot of the organic phase
was dispensed and diluted 1:10 with methanol in 96-well plates containing deuterated
internal standards for each family of lipids (Lipidomix SPLASH from Avanti Polar Lipid).
The lipidomic analysis by NMR (1H-NMR) was conducted using a second aliquot of the
organic phase dryness with Speed Vac. Extracts were reconstituted with a solution of
CD3Cl: CD3OD with 4% D2O and 0.01% TMS (0.067 mM, Eretic Signal 6166 mM).
2.5. GC-HRMS Metabolomics Profiling
Samples were analysed in a 7890A Series gas chromatograph coupled to a 7000 GC-
qTOF from Agilent Technologies using the J&W Scientific HP5-MS (30 m × 0.25 mm
i.d., 0.25 µm film) chromatographic column and helium as carrier gas. Ionization was
done by electronic impact (EI), recording data in Full Scan mode. Quantification was
performed using the corresponding analytical standard for each determined metabolite and
a deuterated internal standard depending on the family of metabolite. Internal standards
used were succinic acid-d4, glycerol-13C3, norvaline, L-methionine-(carboxy-13C, methyl-
d3), D-glucose-13C6, myristic-d27 acid, and alpha-tocopherol-d6.
2.6. LC-HRMS Lipidomics Profiling
The lipid species present in the plasma samples were determined by ultra-high per-
formance chromatography coupled to quadrupole-time of flight high-resolution mass
spectrometry 6550 (UHPLC-qTOF, Agilent Technologies). The ionization was performed
in positive electrospray and mass calibration reference was used along all the analyses to
maintain the mass accuracy below 5 ppm. Lipids were separated on a C18 reversed phase
column (Kinetex C18-EVO, Phenomenex) and a ternary mobile phase (water/methanol/2-
propanol) was used. The quantification of each lipid was made using one analytical
standard and one deuterated internal standard for each lipid family (lysophosphatidyl-
cholines, phosphatidylcholines, sphingomyelins, and triglycerides).
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2.7. 1H-NMR Lipidomic Profiling
1H NMR spectra were recorded at 300K on an Avance III 600 spectrometer (Bruker®,
Germany) operating at a proton frequency of 600.20 MHz using a 5 mm PBBO gradient
probe. Lipidic samples were measured and recorded in procno 11 using a simple presatu-
ration sequence (RD–90◦–ACQ zgpr pulse program in Bruker®) to eliminate the residual
water moisture of deuterated methanol. Solvent pre-saturation with irradiation power of
50 Hz was applied during recycling delay (RD = 5 s) and mixing time. The 90◦ pulse length
was calibrated for each sample and varied from 10.42 to 11.49 ms. The spectral width was
12 kHz (20 ppm), and a total of 64 transients were collected into 64 k data points for each
1H spectrum. The exponential line broadening applied before Fourier transformation was
of 0.3 Hz. The frequency domain spectra were manually phased and baseline-corrected
using TopSpin software (version 2.1, Bruker). After pre-processing and visual checking of
NMR dataset, specific 1H regions of diacylglycerols, triglycerides, and total lipids based on
terminal methyl and methylene signals were identified in the spectra using a comparison
into AMIX 3.9 software. Curated identified regions across the spectra were integrated
using the same AMIX 3.9 software package and exported to an Excel spread sheet in order
to give absolute concentrations. Information about the mass to charge ratio and retention
time is shown in Supplementary Table S1.
2.8. Statistical Analysis
Baseline participants’ characteristics are described as means and standard deviations
(SD) for quantitative variables, and percentages for categorical. Study participants’ char-
acteristics were compared between the two appetite’s assessments using paired t-test for
continuous variables and χ2 tests for categorical variables. Metabolites with equal or more
than 20% of missing values were excluded. For those with less missing values, data were
imputed using the random forest imputation method “missForest” function from the “ran-
domForest” v 4.6-14 R package. A total of 9 metabolites were, therefore, excluded from the
initial metabolomic panel (n = 133) and 124 metabolites remained into the analysis. Rank-
based inverse normal transformation was applied to the metabolomics data to improve
normality. Gaussian regression with an elastic net penalty was used to build a multimetabo-
lite model for the incremental area under the curve (iAUC) of the VAS for satiety (“caret” v
6.0-84 and “glmnet” v 3.0-2 R package) for the first and second study visit. iAUC were calcu-
lated using the trapezoidal integration of pre- and immediately post-preload consumption,
1 h, 2 h, and 3 hours’ satiety ratings (trapz function of “pracma” v 2.2.9 R package). iAUC
scores were adjusted for changes in body weight during the pre-visit weight-loss period
before the first study visit and during the 12 week weight-maintenance period between
the first and second study visit, using the residuals method [15]. A 10 cross-validation (CV)
approach was performed, splitting the whole dataset into training and validation sets (80%
and 20%, respectively). Subsequently, a 10-fold CV was performed within each training
set to estimate the best value of the tuning parameter (lambda) that yielded the minimum
mean-squared error (MSE). Models were optimized using argument best Tune of the “caret”
R package. In order to report the coefficients from each CV iteration, s = “lambda.min” was
selected, as it gives the minimum mean CV error. The alpha parameter was also estimated
using 0.1 increments from 0 (i.e., Ridge regression) to 1 (i.e., Lasso regression). The al-
pha value of the model with the best predicting accuracy in the validation sets was 0.8.
Weighted models for each training-validation datasets (i.e., for every 80–20 split datasets)
were constructed using the metabolite coefficients obtained from the elastic net regression
of each training set. Pearson correlation coefficients (95% confidence interval (CI)) were
computed to assess the performance of the multimetabolite models for iAUC satiety in
the validation set. Pearson correlation coefficients (95% confidence interval (CI)) were
computed to assess the performance of the multimetabolite models for iAUC satiety in
the validation set. This approach was also used to correlate the identified multimetabolite
model with fasted VAS and the amount of energy intake at lunch and dinner in the day of
the study. For reproducibility purposes, the regression coefficients were presented using
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10 iterations of the 10-CV elastic regression approaches in the whole dataset. Pearson’s rank
correlation analysis and scatter plots for the association between each selected metabolite
and the VAS scores were conducted. All the analyses were performed using R statistical
software (v 3.6.1) (R Foundation for Statistical Computing, Vienna, Austria)
3. Results
The general characteristics of the 151 and 140 participants in the first and appetite
assessments are shown in Table 1. The mean age was 47.5 ± 10 years, with a BMI of
27.5 ± 2.0 kg/m2 and 27.7 ± 2.2 kg/m2 for the first and second appetite assessment, re-
spectively. The mean iAUC-VAS was 1056.5 ± 290.1 and 1082.8 ± 285.1, respectively. Total,
High-density lipoprotein (HDL) and Low-density lipoprotein (LDL) cholesterol were sig-
nificantly higher in subjects in the second appetite assessment. The current metabolomics
platforms identified different metabolites, of which triglyceride species 52.3 and 52.2 had
the highest concentrations, while sucrose and docosahexaenoic had the lowest concentra-
tions (Table S1).
Table 2 displays the mean coefficient values and SDs for those metabolites selected
10 times in the 10 CV analyses for the two study visits. In the first study visit analysis,
both glycine and linoleic acid were positively associated with higher iAUC satiety, whereas
sucrose, and two sphingomyelin (SM) species (C32:2 and C38.1) were inversely associ-
ated with increased satiety sensations. Consistently, both glycine and linoleic acid were
positively associated with higher iAUC satiety in the second study visit analysis. Higher
iAUC satiety was also positively associated with C38:4e phosphatidylcholine but only in
the second study visit. In the training set, the unbiased metabolomic profiles acquired
using the 10-fold cross-validation approach were significantly correlated with iAUC satiety
in both study visits (r = 0.37 and r = 0.27, respectively) (Table 3). Similar results were
obtained for fasted VAS (r = 0.22 (0.07, 0.37), p = 0.006). Scatter plots of the metabolites
selected by elastic net and the VAS scores at the first and the second appetite assessment
are shown in Figure 2.
Table 1. Characteristics of the study participants.
Characteristics First Appetite Assessment(n = 151)
Second Appetite Assessment
(n = 140) p-Value
Age, years 48 ± 10 48 ± 10 0.594
Sex, women 74 (117) 75 (105) 0.821
Weight, kg 78.4 ± 9.3 78.9 ± 9.8 0.495
BMI, kg/m2 27.5 ± 2.0 27.7 ± 2.2 0.383
Waist circumference, cm 90.8 ± 8.3 91.4 ± 8.8 0.425
SBP, mm Hg 121 ± 14 121 ± 14 0.820
DBP, mm Hg 77 ± 9 77 ± 9 0.839
Glucose, mg/dL 91.8 ± 8.7 91.0 ± 8.3 0.439
Total cholesterol, mg/dL 177.5 ± 31.7 194.9 ± 37.2 <0.001
HDL-C, mg/dL 51.0 ± 12.7 61.4 ± 15.5 <0.001
LDL-C, mg/dL 108.5 ± 27.2 116.2 ± 32.0 0.029
Triglycerides, mg/dL 90.1 ± 36.0 85.6 ± 41.0 0.324
Total energy intake, kcal/day 1523.27 ± 572.05 1552.60 ± 562.28 0.658
Carbohydrates intake (%E) 40.03±7.25 40.35±7.00 0.704
Protein intake (%E) 21.44±5.19 19.89±4.16 0.006
Fat intake (%E) 35.63±7.66 36.07±6.62 0.609
Fiber, g/day 17.89±8.04 18.15±7.98 0.784
iAUC-VAS 1056.5 ± 290.1 1082.8 ± 285.1 0.769
Mean ± SD or % (N). Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein; iAUC-VAS, integrated area under the curve of the visual analogic scale
of satiety.
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Table 2. List of coefficients of metabolites selected 10 times in the ten times iterated 10-fold-cross
validation of the elastic continuous regression analyses in the whole Satiety Innovation (SATIN)
dataset and including the two satiety assessments.
Metabolites Elastic Gaussian Regression(First Assessment)
Elastic Gaussian Regression
(Second Assessment)
Mean ± SD Mean ± SD
Glycine 41.70 ± 7.32 31.83 ± 3.30
Linoleic Acid 5.80 ± 3.51 9.20 ± 3.17
Sucrose −7.71 ± 6.11 -
C32.2 SM −9.91 ± 4.22 -
C38.1 SM −19.92 ± 2.34 -
C38.4 ePC - 7.11 ± 2.90
Data are shown as mean of elastic net regression coefficient ± standard deviation (SD). SM, Sphingomyelin; PC,
phosphatidylcholine.














First assessment 0.37 (0.23, 0.51) <0.001 2 3
Second assessment 0.27 (0.11, 0.42) 0.001 3 -
All metabolites were selected 10 times in the cross-validation procedure for the elastic net Gaussian regression
using “lambda.min” option. Abbreviations: 95%CI, 95% confidence interval.
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The duration and the intensity of postprandial satiety result from a complex interaction
between internal and external factors including physiology, cognitive and sensory factors,
as well as intrinsic characteristics of the meal (i.e., energy and nutrient content) [15].
A complex cascade of hormonal and other molecules are secreted to be integrated in
the brain, which influence the satiety response [16]. However, individual differences result
in variability in the processing of satiety that can lead to overeating due to a diminished
sensitivity to satiety signals and increased susceptibility to the food environment and its
obesogenic effects [17]. It has been proposed that some of these individual differences in
satiety responsiveness have a genetic basis [17] but other causal factors can influence and
become biomarkers of appetite [18].
Our results showed a significant relationship between higher circulating glycine con-
centrations with a higher satiety response. Glycine is present in the nervous system and
acts as a neurotransmitter binding to several receptors and inhibiting many chemical pro-
cesses [19]. Its effects seem to be similar to the gamma-Aminobutyric acid (GABA) action.
An increased glycine function effect may result as a similar increment in the GABAergic
neurotransmission [19]. It has been reported that low plasma concentrations of glycine are
associated with obesity and T2D and that in the long-term its deficiency may be related to
the origin of other metabolic disorders like insulin resistance and nonalcoholic fatty liver
disease [20]. The association between plasma concentrations of amino acids and satiety
has been previously assessed in a post Roux-en-Y gastric bypass surgery sample [21].
According to this study, participants with greater postprandial satiety responses had a
significantly higher median iAUC of several plasma amino acids concentrations, including
glycine. The ‘protein-stat theory’ proposed by Millward suggested that amino acids sensors
could potentially provide a mechanism in which the energy demands originating from
fat-free mass are translated into food intake [21].
Higher circulating concentrations of linoleic acid were also positively associated with
higher postprandial satiety. To our knowledge, there is no previous study on circulating
individual fatty acids relationships with appetite. Reduced appetite ratings were observed
acutely after administering emulsions enriched with linoleic acid compared with oleic
and stearic acid through upper intestinal perfusions to lean human subjects [22]. A pre-
vious randomized, crossover study of healthy subjects concluded that when infused into
the ileum, triacylglycerol with unsaturated fatty acids including linoleic acid increase sati-
ety compared with triacylglycerol with saturated fatty acids [23]. Total levels of free fatty
acids have been previously associated with appetite control [8], however, no indication of a
circulating individual fatty acids effect on appetite has been established yet. Results from a
study that aimed to identify a potential effect of pharmacological modifications of fatty acid
metabolism on human satiety showed that an inhibitor of lipogenesis increased the inten-
sity and duration of satiety. It was hypothesized that this effect may be produced through
the increment of non-esterified fatty acids, increasing their disposal for oxidation [24].
Although not consistently found through the appetite assessments, the SMs C32:1 and
C38:2 were inversely associated with satiety sensations in the first assessments. A reduction
in the sphingolipid-1-phosphate to C14:1 ceramide ratio was correlated with a reduction in
postprandial satiety via the neuropeptide Y-like receptor (NepYr) in Drosophila, supporting
the role of ceramides in appetite regulation and caloric-intake dependent obesity [25].
Since SMs are synthesized from ceramides, lower SM levels could be interpreted as lower
ceramide concentrations that are inversely associated with increased satiety. Whether SM
could modulate satiety via the NepYr deserves further investigation [25].
Although there are small amounts of sucrose in blood as it is mainly hydrolyzed and
absorbed as glucose and fructose, in our study, plasma sucrose levels were associated with
lower postprandial satiety on the first study visit. The effect of sucrose and other types of
sugars on the appetite mechanisms is still not fully understood. In short test meals, sucrose
intake produces an immediate insulin secretion, producing appetite regulation signals
that contribute to satiety and the suppression of appetite and food intake [26]. However,
the long-term effect is still widely debated due to the vast body of data, which inversely
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associate sucrose consumption with body mass index and the risk of obesity [27]. A pre-
vious study performed in animal models with the objective of recognising the effects of
sucrose and other types of sugars on peripheral and central appetite showed that after 24 h
of drinking sucrose, total serum peptide YY (PYY), a peripheral appetite signal [28], was
significantly increased compared to a water control [29]. Yet, after two weeks consuming
sucrose solutions, the serum PYY concentration was significantly lower that the water
control group. Results also showed an increased in the caloric intake and in the body
weight gain in this group, as an up-regulation of the hypothalamic CB1 mRNA, being
CB1 an endocannabinoid receptor involved in feeding reward [30]. On the other hand,
they also observed an increase of serum levels of leptin, an anorexigenic hormone [31],
and a down-regulation of hypothalamic NPY mRNA, a hunger neuropeptide [32]. Au-
thors later hypothesized that the caloric over-consumption and weight gain produced by
the sucrose consumption may be associated to the activation of hunger signals and reward
components, as well as the decline of satiety signals. Additionally, the increment in serum
leptin and the down-regulation of NPY mRNA may be a possible defence mechanism
against the weight-promoting effect of the sugar solutions. Interestingly, the identified
metabolomic profile was not significantly correlated with energy intake at lunch and dinner.
We also found no correlation between VAS and energy intake, which is in line with previ-
ous studies suggesting that self-reported appetite ratings do not reliably predict energy
intake [33]. The feeling of appetite may affect energy intake but also be a consequence of
the amount and type of food/meal eaten. Therefore, the metabolites identified for VAS do
not seem to be related to the amount of energy ingested.
Our study has limitations that need to be acknowledged. First, even though VAS are
widely used to assess the physiological and psychological dimensions of appetite sensa-
tions, and provide reproducible and valid information, they were self-report and, therefore,
subject to some degree of measurement error [12]. For this reason, we assessed the relation-
ship between metabolites and VAS on two separate occasions. Secondly, we evaluated a
sample of individuals with overweight and obesity that could limit the generalizability of
our results to other populations. Thirdly, due to the cross-sectional design, causation and
direction of causality cannot be inferred; therefore, currently both directions are plausible
and require further investigation. Finally, the lack of reproducibility in four of the selected
metabolites could be due to a smaller sample size in the second appetite assessment or
due to other confounders beyond those considered in our study. On this regard, it is
important to highlight that no significant differences were observed in anthropometrical
and nutritional measurements between the two assessments, while breakfast’s food and
nutritional composition was equal between the assessments.
In conclusion, the present study identified a small set of metabolites moderately asso-
ciated with postprandial satiety in a study population with overweight/obesity. These find-
ings could help us to better understand the metabolic pathways implicated in satiety and
in the future may result in a helpful tool for the design of more effective strategies for
appetite control.
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